Hercules, CA — November 3, 2013 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of its CFX Automation System II, a robotic plate handler that enables high-throughput, walk-away real-time PCR automation for all Bio-Rad CFX Real-Time PCR Detection Systems.
The new system is ideally suited to meet the high-throughput real-time PCR requirements of today’s drug discovery and screening workflows by facilitating hands-off, around-the-clock data generation and analysis.
The CFX Automation System II can be integrated with one or two CFX Systems while maintaining a small footprint, and includes easy-to-use software that makes automation accessible to all researchers. It is easily integrated with laboratory information management systems (LIMS) to facilitate sample tracking, save time, and minimize human error.
The CFX Automation System II allows laboratories to:
- Save valuable lab space — operate two CFX Systems with a single plate handler using a fraction of the space required by other systems
- Meet changing throughput demands — begin with one real-time system and scale up to two systems when required
- Have confidence in your results — software allows for easy integration of wet-lab validated PrimePCR™ Assays (available in the U.S., Canada, Australia, New Zealand, Singapore, and E.U. only).
Please visit www.bio-rad.com/CFXautomationIIpr for more information about Bio-Rad’s CFX Automation II System.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of products for life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and industry customers through its global network of operations. The company employs approximately 7,800 people worldwide and had revenues exceeding $2.1 billion in 2013. Visit us at www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
Richard Kurtz
Bio-Rad
510-741-5638
Richard_Kurtz@bio-rad.com
Ken Li
Chempetitive Group
312-997-2436 x 112
kli@chempetitive.com